Oral News and Research

RSS

Over 12,000 participants already registered for 25th Anniversary EAU Congress

The upcoming 25th Anniversary EAU Congress in Barcelona from April 16 to 20 promises to be one of the EAU's biggest meetings in recent years with around 12,100 participants already registered to attend the annual urological event.

12 Apr 2010

Rib-X Pharmaceuticals to present delafloxacin Phase 2 study data at 20th ECCMID

Rib-X Pharmaceuticals, Inc., a development-stage antibiotics company with a broad product pipeline based on its innovative discovery platform, today announced that an oral presentation of data for delafloxacin, its lead antibiotic candidate, will be given at the 20th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 10-14, in Vienna, Austria by Paul G. Ambrose, Pharm.D, FIDSA, Director, Institute for Clinical Pharmacodynamics, Ordway Research Institute.

12 Apr 2010

Phase I study of Affinium Pharmaceuticals' AFN-1252 for MRSA initiated

Affinium Pharmaceuticals announced today the commencement of a Phase I study in the United States for its novel molecular entity, AFN-1252, a first in class antibiotic candidate focused on the oral and IV treatment of susceptible and highly resistant strains of Staphylococcus aureus.

12 Apr 2010

High OOP costs discouraging many cancer patients from filling prescriptions

A new study presented today at the Academy of Managed Care Pharmacy's 22nd Annual Meeting finds that one in six cancer patients with high out-of-pocket (OOP) costs abandons their medication. The study by Prime Therapeutics (Prime), a thought leader in pharmacy benefit management, found patients with an OOP cost greater than $200 were at least three times more likely to not fill their prescription than those with OOP costs of $100 or less.

12 Apr 2010

Resverlogix highlights features of RVX-208 drug at ATVB conference

Resverlogix Corp. announced today that key scientific data was communicated in an oral presentation highlighting the novel features of RVX-208, the Company's lead drug, during the Atherosclerosis, Thrombosis, Vascular Biology conference being held in San Francisco, California.

12 Apr 2010

Cempra to make poster presentations on CEM-101 and CEM-102 at ECCMID 2010

Cempra Pharmaceuticals today announced poster presentations on its novel antibiotic CEM-101, a next-generation macrolide, and CEM-102, the company's proprietary front-loading oral dosing regimen of sodium fusidate, at the 20th European Congress of Clinical Microbiology and Infectious Disease, April 10 to 13, 2010, in Vienna Austria.

12 Apr 2010

AED Vimpat to be the subject of numerous studies and analyses at AAN meeting

The antiepileptic drug Vimpat- (lacosamide) (C-V) will be the subject of numerous studies and analyses-both UCB-sponsored and independent-at the 62nd annual American Academy of Neurology meeting, taking place at the Metro Toronto Convention Centre in Toronto from April 10-17.

9 Apr 2010

Zeria to market, distribute, and sell HemCon's wound and oral care dressings in Japan

HemCon Medical Technologies, Inc., an innovative developer of advanced medical products, is proud to announce the signing of an exclusive licensing agreement with Zeria Pharmaceuticals Co. Ltd., a leading pharmaceutical and consumer healthcare products company. Through this partnership, Zeria will market, distribute, and sell HemCon's line of revolutionary wound and oral care dressings throughout Japan.

9 Apr 2010

Keryx Biopharmaceuticals commences Phase 3 registration clinical trial for perifosine

Keryx Biopharmaceuticals, Inc. announced today the initiation of a Phase 3 registration clinical trial for KRX-0401 (perifosine), the Company's novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, for the treatment of patients with refractory advanced colorectal cancer.

9 Apr 2010

Æterna Zentaris commences perifosine Phase 3 registration trial

Æterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced the initiation of a Phase 3 registration clinical trial with perifosine (KRX-0401) ), the Company's novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, for the treatment of refractory advanced colorectal cancer.

9 Apr 2010

ZIOPHARM Oncology commences Phase I/II study of Zybulin for metastatic breast cancer

ZIOPHARM Oncology, Inc., announced today it has initiated a Phase I/II study at Memorial Sloan-Kettering Cancer Center for the novel, mathematically - determined administration of oral indibulin (Zybulin™ or ZIO-301) in the treatment of metastatic breast cancer.

9 Apr 2010

Cubist Pharmaceuticals initiates dosing in Phase 2 trial with CB-183,315 for diarrhea due to CDAD

Cubist Pharmaceuticals, Inc., a leading acute care therapeutics company, today announced the enrollment and dosing of the first subject in its Phase 2 trial with CB-183,315, an antibacterial drug candidate intended to treat patients with a severe and sometimes life-threatening diarrhea caused by Clostridium difficile known as C. difficile-associated diarrhea, or CDAD. The trial is expected to enroll more than 200 subjects at 28 sites in the United States and Canada.

8 Apr 2010

GETA receives "Fast Track" designation from FDA for Tesetaxel: BeaconEquity.com

BeaconEquity.com announces an investment report featuring biopharmaceutical company Genta Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

8 Apr 2010

Telaprevir-based regimens increase rates of SVR in patients with genotype 1 HCV infection

In a clinical trial known as PROVE 3 published in this week's New England Journal of Medicine, treatment with telaprevir-based regimens significantly increased rates of sustained viral response (SVR) in patients with genotype 1 hepatitis C virus (HCV) infection who did not achieve SVR with at least one prior course of pegylated-interferon and ribavirin therapy.

8 Apr 2010

Cempra Pharmaceuticals announces schedule of poster presentations at ECCMID 2010

Cempra Pharmaceuticals today announced its schedule of poster presentations at the 20th European Congress of Clinical Microbiology and Infectious Disease (ECCMID) in Vienna, Austria, on April 10-13, 2010.

8 Apr 2010

Parents lack understanding of causes, signs and symptoms of dehydration in children

Dehydration is a condition that can have a significant impact on children and, if left untreated, may lead to serious complications and hospitalization. A national survey of more than 800 parents with children between the ages of one month and 10 years found that three out of five parents reported needing to know more information about dehydration, such as when to see a physician, warning signs, and treatment, if their child became sick - pointing to a greater need for awareness and education around the condition and its treatment.

From Baxter International Inc. 8 Apr 2010

Loyola University Medical Center to offer free screenings for oral, head and neck cancer

Oral, head and neck cancers — most of which are preventable — account for approximately 3 percent of all cancer cases in the United States, according to the American Cancer Society. In 2009, more than 35,000 Americans were diagnosed with these cancers and 7,600 died.

8 Apr 2010

Prague hosts 12th European Congress of Endocrinology

The 12th European Congress of Endocrinology is taking place in Prague from 24-28 April 2010.

8 Apr 2010

New studies supporting Teva Pharmaceutical Industries' CNS portfolio to be presented at AAN 2010

Teva Pharmaceutical Industries Ltd. today announced that several new studies supporting the company's innovative central nervous system portfolio will be presented at the 62nd American Academy of Neurology Annual Meeting in Toronto, April 10-17, 2010.

8 Apr 2010

Encouraging results from OptiNose's sumatriptan Phase II study for migraine

OptiNose, a leader in nasal drug delivery systems, is pleased to announce the publication in Cephalalgia of results from its Phase II clinical study investigating the efficacy and tolerability of its novel, intranasal drug/device product for the treatment of migraine.

8 Apr 2010

Oral News and Research

Over 12,000 participants already registered for 25th Anniversary EAU Congress

Rib-X Pharmaceuticals to present delafloxacin Phase 2 study data at 20th ECCMID

Phase I study of Affinium Pharmaceuticals' AFN-1252 for MRSA initiated

High OOP costs discouraging many cancer patients from filling prescriptions

Resverlogix highlights features of RVX-208 drug at ATVB conference

Cempra to make poster presentations on CEM-101 and CEM-102 at ECCMID 2010

AED Vimpat to be the subject of numerous studies and analyses at AAN meeting

Zeria to market, distribute, and sell HemCon's wound and oral care dressings in Japan

Keryx Biopharmaceuticals commences Phase 3 registration clinical trial for perifosine

Æterna Zentaris commences perifosine Phase 3 registration trial

ZIOPHARM Oncology commences Phase I/II study of Zybulin for metastatic breast cancer

Cubist Pharmaceuticals initiates dosing in Phase 2 trial with CB-183,315 for diarrhea due to CDAD

GETA receives "Fast Track" designation from FDA for Tesetaxel: BeaconEquity.com

Telaprevir-based regimens increase rates of SVR in patients with genotype 1 HCV infection

Cempra Pharmaceuticals announces schedule of poster presentations at ECCMID 2010

Parents lack understanding of causes, signs and symptoms of dehydration in children

Loyola University Medical Center to offer free screenings for oral, head and neck cancer

Prague hosts 12th European Congress of Endocrinology

New studies supporting Teva Pharmaceutical Industries' CNS portfolio to be presented at AAN 2010

Encouraging results from OptiNose's sumatriptan Phase II study for migraine

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News